XML 270 R213.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Disclosures about major customers and credit risk (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Percentage of entity's revenue (in percent) |  |  |  | 8.00% |
Net sales | € 41,081 | € 37,817 | [1] | € 37,651 | [1]
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 41,081 | 37,817 | [1] | 37,651 | [1]
Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 41,081 | 37,817 | [2],[3] | 37,651 | [3],[4],[5]
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 41,081 | 37,817 | [2],[3] | 37,651 | [3],[4],[5]
Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 1,316 | 1,266 | [3] | 1,309 | [3]
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 1,316 | 1,266 | [3] | 1,309 | [3]
Launches | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 4,535 | 2,237 | [3] | 951 | [3]
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | € 4,535 | € 2,237 | [3] | € 951 | [3]
Largest customers |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Percentage of entity's revenue (in percent) | 34.00% |  |  |  |
Customer one |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Percentage of entity's revenue (in percent) | 15.00% | 13.00% |  | 13.00% |
Customer two |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Percentage of entity's revenue (in percent) | 11.00% | 10.00% |  | 9.00% |
Customer three |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Percentage of entity's revenue (in percent) | 8.00% | 8.00% |  |  |
Europe |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | € 9,027 | € 8,816 | [6] | € 8,490 | [7]
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 9,027 | 8,816 | [6] | 8,490 | [7]
Europe | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 9,027 | 8,816 |  | 8,490 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 9,027 | 8,816 |  | 8,490 |
Europe | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 204 | 157 |  | 112 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 204 | 157 |  | 112 |
Europe | Launches | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 960 | 491 |  | 215 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 960 | 491 |  | 215 |
US |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 19,986 | 17,262 | [6] | 16,986 | [7]
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 19,986 | 17,262 | [6] | 16,986 | [7]
US | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 19,986 | 17,262 |  | 16,986 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 19,986 | 17,262 |  | 16,986 |
US | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 736 | 730 |  | 767 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 736 | 730 |  | 767 |
US | Launches | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 2,998 | 1,533 |  | 623 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 2,998 | 1,533 |  | 623 |
Other Countries In Segment Results [Member] | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 12,068 | 11,739 |  | 12,175 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 12,068 | 11,739 |  | 12,175 |
Other Countries In Segment Results [Member] | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 376 | 379 |  | 430 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | 376 | 379 |  | 430 |
Other Countries In Segment Results [Member] | Launches | Biopharma (operating segment) |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |
Net sales | 577 | 213 |  | 113 |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Net sales | € 577 | € 213 |  | € 113 |
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4] | (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5] | (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax).
[6] | (a)Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[7] | (a)Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of the entity's revenue. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 34 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_PercentageOfEntitysRevenue
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure of information about major customers and credit risk. + References No definition available. + Details
Name: | sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicsVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LaunchesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=sny_LargestCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=sny_CustomerOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |